SEC Form 4 · accession 0001179110-17-011453
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katrine Bosley
Officer — President and CEO · Director
Period of report
Aug 10, 2017
Accepted (ET)
Aug 14, 2017 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2017 | S | 10,000 | $20.016 | D | 1,431,095 | D | |
| Common StockF2 | Aug 11, 2017 | S | 6,666 | $20.0195 | D | 1,424,429 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $20.00 to $20.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.